Two microscopy images of human colon organoids. The left image shows an organoid with the FBXW7 mutation (colorectal cancer) and the right image shows an organoid without the mutation (wild type). The ...

New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC). Background: KRAS mutated CRC ...

Three papers published this month in the open access general medical journal PLoS Medicine investigate how tumors respond to a an important class of drugs used in cancer chemotherapy, known as ...

Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...

The RAMOSE and RELAY trials revealed the capacity and constraints of combination therapy with ramucirumab (Cyramza) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC). The phase II RAMOSE ...

TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...